102例老年非小细胞肺癌患者的治疗方法

Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer.

作者信息

Cihan Sener, Odabas Hatice, Ozdemir Nuriye Yildirim, Yazilitas Dogan, Babacan Nalan Akgul

机构信息

Department of Medical Oncology, Okmeydani Training and Research Hospital, 34100 Sisli, Istanbul, Turkey.

Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, 34860 Kartal, Istanbul, Turkey.

出版信息

World J Oncol. 2015 Feb;6(1):276-282. doi: 10.14740/wjon894w. Epub 2015 Feb 14.

DOI:10.14740/wjon894w

PMID:29147416

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5649946/

Abstract

BACKGROUND

The life expectancy and presence of co-morbidities cause reservations in treatment decisions for elderly patients with cancer. In this study, we retrospectively evaluated 102 patients who are considered as middle-old aged (aged 75 - 84) by gerontologists.

METHODS

Medical records of patients were reviewed. One hundred and two patients with a diagnosis of non-small cell lung cancer (NSCLC) whose follow-up ended with death between March 2006 and May 2013 were examined.

RESULTS

The median age at diagnosis was 77 (75 - 85) years. Thirty-three patients (67.6%) were over 80 years old. The number of patients with metastasis was 57 (55.8%). Forty-two (41.2%) patients had stage IIIA and IIIB disease. Fifteen of the metastatic patients (26.3%) were given chemotherapy, while 12 of the non-metastatic patients (26.6%) were given chemotherapy. Of the non-metastatic patients, 25 (55.6%) were treated with radiotherapy, and five (11.1%) were treated with chemotherapy. The median duration of follow-up was 4 (1-55) months. Progression-free survival (PFS) was 4 months in non-metastatic patients, and 3 months in metastatic patients. Overall survival (OS) was 4 months. OS rates for 1 and 2 years were 10% and 2%.

CONCLUSION

Chemotherapy and radiotherapy may be administered even to patients of this age group. The beneficial effect of chemotherapy in patients with metastasis on OS is an important finding of our study.

摘要

背景

预期寿命和并存疾病使得老年癌症患者的治疗决策存在顾虑。在本研究中，我们回顾性评估了102名被老年病学家视为中老年（75 - 84岁）的患者。

方法

查阅患者的病历。研究了102例诊断为非小细胞肺癌（NSCLC）且随访至2006年3月至2013年5月期间死亡的患者。

结果

诊断时的中位年龄为77（75 - 85）岁。33例患者（67.6%）年龄超过80岁。发生转移的患者有57例（55.8%）。42例（41.2%）患者患有IIIA期和IIIB期疾病。15例转移患者（26.3%）接受了化疗，而12例非转移患者（26.6%）接受了化疗。在非转移患者中，25例（55.6%）接受了放疗，5例（11.1%）接受了化疗。中位随访时间为4（1 - 55）个月。非转移患者的无进展生存期（PFS）为4个月，转移患者为3个月。总生存期（OS）为4个月。1年和2年的OS率分别为10%和2%。